A humanized monoclonal antibody directed against integrin αvβ6, which activates pro-TGF-β1 and pro-TGF-β3 [74], is currently in phase II trials in patients with idiopathic pulmonary fibrosis [127]. This evidence concerns the gene TGFB3 and pulmonary fibrosis.